s.zielinski95/100
Consistency: 10 lots, purity band under 1.0 points wide. Tracking record corresponded to consignment position at every hop. No adverse observation.
SSA — Shanghai Sigma-Audley New Material Technology Co., Ltd.
Shanghai, CN · established 2018. The index holds 219 assay reports across 39 batches and 27 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where SSA sells
Shanghai Sigma-Audley New Material Technology Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit SSA at shanghaisigmaaudley.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Shanghai Sigma-Audley New Material Technology Co., Ltd.
- Short code in this index
- SSA
- Also known as
- SSA · SSA Biotech · Shanghai Sigma-Audley New Material Technology
- City
- Shanghai
- Region
- Shanghai
- Country
- CN
- Established
- 2018
- First record in index
- 15 Apr 2024
- Most recent record
- 18 Jul 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
14.2%
n=219
Retail, shipped to the buyer
63.9%
n=219
Direct to the laboratory
16.9%
n=219
Median courier leg, direct despatch
7d
n=37
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 31 | 14.2% |
| Retail purchase, shipped to the buyer | 113 | 51.6% |
| Retail purchase via a third-party forwarder | 27 | 12.3% |
| Supplier despatch direct to the laboratory | 37 | 16.9% |
| Laboratory retained-sample archive | 11 | 5.0% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 219 SSA records the index holds, 31 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 15 of the 27 compounds SSA is represented by here — IGF-1 DES (1-3), BPC-157, Semaglutide, Semax, Sermorelin, SS-31 (Elamipretide) and 9 further compounds. Those are the SSA lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents SSA stock held in Germany, with a transit of 2 working days against a quoted 2. Germany is the only regional stock location named anywhere in SSA's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is SSA's own reviewers: 3 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. Where SSA despatched a sample direct to a laboratory, the courier leg ran a median 7 days across 37 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.24%
n=219
Interquartile range
0.81pp
n=219
10th percentile
97.48%
n=219
Pass rate vs index spec
82.2%
n=219
Median recovery vs claim
98.4%
n=134
Median water
4.66%
n=219
Median |mass error|
2.3ppm
n=181
Records carrying a flag
38.8%
n=219
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.84pp
n=27
Index median spread
0.67pp
n=28
Lots tested 3+ times
27
n=39
Across the 27 SSA lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.84 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.06pp
n=39
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
59%
n=39
Divergences beyond 1 pp
0%
n=39
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.16%
n=171
Supplier-supplied median
98.78%
n=37
Supplier-supplied share of records
16.9%
n=219
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of SSA batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
72/100
n=39
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 69% | 25 points | |
| Peptide content stated | 64% | 20 points | |
| Endotoxin stated | 33% | 15 points | |
| Named impurities rather than a total | 29% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| BPC-157 | Tissue-repair | 23 | 98.17 | 99.16 | -0.99 | 98.0 | 70 |
| Semaglutide | Incretin | 23 | 98.02 | 98.89 | -0.87 | 97.0 | 100 |
| Tirzepatide | Incretin | 21 | 97.97 | 98.55 | -0.58 | 97.0 | 100 |
| Retatrutide | Incretin | 20 | 97.68 | 98.37 | -0.69 | 96.5 | 100 |
| IGF-1 DES (1-3) | Growth-hormone | 14 | 99.15 | 99.12 | +0.03 | 95.0 | 100 |
| SS-31 (Elamipretide) | Metabolic | 14 | 97.97 | 99.53 | -1.57 | 98.5 | 7 |
| GHK-Cu | Tissue-repair | 13 | 98.37 | 98.56 | -0.19 | 97.0 | 100 |
| Semax | Neuroactive | 12 | 98.69 | 99.46 | -0.77 | 98.5 | 67 |
| MOTS-c | Metabolic | 12 | 98.10 | 99.13 | -1.03 | 98.0 | 58 |
| TB-500 | Tissue-repair | 12 | 98.54 | 99.53 | -0.99 | 98.5 | 67 |
| PEG-MGF | Growth-hormone | 8 | 96.05 | 97.75 | -1.70 | 92.0 | 100 |
| Sermorelin | Growth-hormone | 6 n=6 | 98.50 | 99.06 | -0.55 | 98.0 | 100 |
| Thymosin α1 | Tissue-repair | 6 n=6 | 98.39 | 99.40 | -1.02 | 97.5 | 100 |
| CJC-1295 with DAC | Growth-hormone | 5 n=5 | 98.41 | 98.95 | -0.54 | 97.5 | 100 |
| Humanin (HNG) | Metabolic | 4 n=4 | 99.06 | 99.12 | -0.06 | 97.5 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 4 n=4 | 98.65 | 99.38 | -0.73 | 98.5 | 50 |
| LL-37 | Tissue-repair | 4 n=4 | 98.16 | 98.90 | -0.75 | 96.5 | 100 |
| Mazdutide | Incretin | 3 n=3 | 98.87 | 98.14 | +0.73 | 96.5 | 100 |
| Vilon | Short | 3 n=3 | 99.15 | 99.65 | -0.50 | 99.0 | 100 |
| L-Carnosine | Short | 3 n=3 | 98.95 | 99.58 | -0.63 | 99.0 | 33 |
| GHRP-2 | Growth-hormone | 2 n=2 | n<3 | 99.28 | — | 99.0 | 100 |
| 5-Amino-1MQ | Non-peptide | 2 n=2 | n<3 | 99.45 | — | 98.0 | 100 |
| Enclomiphene citrate | Non-peptide | 1 n=1 | n<3 | 99.44 | — | 98.5 | 0 |
| L-Glutathione (reduced) | Short | 1 n=1 | n<3 | 99.33 | — | 98.5 | 100 |
| Melanotan II | Melanocortin-receptor | 1 n=1 | n<3 | 99.42 | — | 98.5 | 100 |
| Glucagon | Incretin | 1 n=1 | n<3 | 99.20 | — | 98.0 | 100 |
| Ipamorelin | Growth-hormone | 1 n=1 | n<3 | 99.47 | — | 99.0 | 0 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 0 | 0 | n<3 | — | 0 |
| 2024-Q2 | 3 | 16 | 99.12 | 98.07–99.71 | 1 |
| 2024-Q3 | 6 | 29 | 98.11 | 97.16–98.85 | 10 |
| 2024-Q4 | 3 | 23 | 98.58 | 96.98–99.28 | 4 |
| 2025-Q1 | 3 | 19 | 98.29 | 97.87–98.96 | 1 |
| 2025-Q2 | 3 | 7 | 99.18 | 98.68–99.41 | 1 |
| 2025-Q3 | 9 | 50 | 98.14 | 97.20–99.48 | 26 |
| 2025-Q4 | 4 | 29 | 97.36 | 95.57–98.51 | 21 |
| 2026-Q1 | 2 | 10 | 98.37 | 97.16–99.15 | 0 |
| 2026-Q2 | 6 | 36 | 98.20 | 97.57–99.19 | 21 |
| 2026-Q3 | 0 | 0 | n<3 | — | 0 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 100 | 98.28 | +0.00 | 98.28 |
| PeptideMeter | 34 | 98.20 | -0.05 | 98.25 |
| Medutest | 39 | 98.28 | +0.08 | 98.20 |
| VendorInvestigate | 19 | 98.12 | -0.11 | 98.23 |
| Nordanalyt | 17 | 98.16 | +0.02 | 98.14 |
| Kestrel | 10 | 98.50 | +0.24 | 98.26 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
91.0/ 1001,124 ratings across the index network
l.norgaard99/100
Water content by Karl Fischer, method named. Vial-to-vial mass variation under 2%. Submitted to the index in full.
c.espinoza98/100
Storage condition for the stability statement stated on the certificate. Gradient and column chemistry stated. Not medical advice.
so.okonkwo97/100
Published stock status matched availability. Same-day dispatch. Further submissions on later lots would improve coverage.
s.moreau96/100
Cross-check: Janoshik and VendorInvestigate, same lot, agreement to 0.1 points. Both agree with the declared figure. Pricing published against lot size on request; the quoted figure was the invoiced figure. n=1, declared as n=1.
me.beaulieu95/100
Release signed and dated, named individual. Declared and independent figures differ by less than repeatability. Documentation practice, not a single purity figure, is the substance here.
p.baptista99/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Signature and release date present. Figures as reported by the named service. Not reproduced by the index.
co.vasquez98/100
Blind submission of semaglutide 5 mg to Medutest, origin withheld. 98.5% against 98.7% declared. Vial-to-vial mass variation under 2%.
b.nakamura97/100
Documentation complete at first issue. No supplementary request raised. Supplementary certificate produced without demur.
e.villalobos96/100
Retention time assigned to the principal peak, printed. Identity confirmed by two orthogonal methods. n=1, declared as n=1.
i.sorensen100/100
Every vial in the consignment sound on inspection: flange, crimp, cake. Cost per assayed milligram sits with the documentation supplied, and the certificate carries every field the index scores.
s.sorensen99/100
Lot SSA-24-415 submitted to PeptideMeter. Declared 97.7%, reported 98.0%. Delta inside method repeatability. Not medical advice.
a.ramos95/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone.
g.balogun96/100
Packing: the desiccant sachet actually inside the secondary container. Vial-to-vial mass variation under 2%.
c.kjaer99/100
Peptide content reported separately from chromatographic purity across all 10 certificates held.
c.novak95/100
Cold chain intact. Phase-change pack solid at arrival, day 6. Reorder at 10 months within 0.1 points of the original.
r.kirchner96/100
Batch record supplied in full on request, attached rather than summarised. Quote itemised by lot size, honoured as issued, and reconciled against the packing list on arrival.
a.perrin100/100
Tracking number live from despatch and accurate at every scan. Technical response inside four hours, working day.
l.agyeman95/100
Labelling printed, lot and date legible on every unit examined. n=1, declared as n=1.
m.kirchner96/100
Transit 2 days from stock held in Germany against a quoted 2. Customs documentation correct at first presentation. Vial-to-vial mass variation under 2%.
j.krastev100/100
Phase-change pack hard on arrival, day 3. Supplementary certificate produced without demur.
j.ogunleye96/100
Counter-ion identity and content answered quantitatively, one working day. Independent verification of individual lots still required.
t.sorensen99/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart. Minimum order stated up front in vials and in grams, so the quotation needed no clarification.
e.rasmussen100/100
Eight orders, eight lot-specific certificates, each attached at despatch. Nothing needed chasing.
ma.ndiaye96/100
Repeat determination at 24 months: 97.4%. Original: 97.4%. No drift detected in this sample. Evidence base adequate for a rating on this criterion.
l.pereira95/100
Direct-supply material 97.9%. Intermediary vial, same nominal description, 97.7%. Not medical advice.
Block 12
Most recent records
Block 13
Contributor annotations on SSA records 346
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on SSA material are below, each linked to the record it sits on.
Doubling column length gains 40 % resolution and doubles the run. On a routine release method that trade is usually declined, and the certificate should say which method was run.
A retail vial is also a test of the label. Declared claim 2 mg against what the gravimetry recovers is a question only a purchased vial can answer honestly.
Valley height relative to the smaller peak is the practical criterion an operator uses, and it is not on the report. Resolution is a proxy for it and an imperfect one on asymmetric pairs.
Rounding convention is the least of what a certificate carries. Lot code, method, wavelength and release date are the fields that let a reader reconstruct the figure, and the index scores those separately on the documentation rubric.
Expanded uncertainty on a purity figure is about half a point. A declaration rounded to the nearest half point is quantising at roughly the resolution of the measurement, which is defensible practice rather than sloppy practice.
A reference standard on the same sequence would upgrade this from a good mass to a traceable one. The distinction matters where a result is going to be cited rather than merely read.
Every named impurity on this record has a mass defect consistent with its structural assignment. That is the check that distinguishes an assignment from a guess.
The gap between 97.89 % and the class specification should be read against an expanded uncertainty of roughly ±0.5 pp. A shortfall inside that band is not a finding; a shortfall well outside it is.
Every annotation the index holds on SSA material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what SSA itself publishes, open shanghaisigmaaudley.com → alongside.
Block 14
Where to buy SSA
Shanghai Sigma-Audley New Material Technology Co., Ltd. sells direct from shanghaisigmaaudley.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the SSA store at shanghaisigmaaudley.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.